

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of October 2025

Commission File No. 001-39621

---

**OPTHEA LIMITED**  
(Translation of registrant's name into English)

---

Level 4  
650 Chapel Street  
South Yarra, Victoria, 3141  
Australia  
(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

---

---

**EXHIBIT INDEX**

---

<b>Exhibit</b>	<b>Description</b>
99.1	Press Release - Opthea Received A\$10.8 million R&D Tax Incentive

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

**OPTHEA LIMITED**  
(Registrant)

By: /s/ Jeremy Levin  
Name: Jeremy Levin  
Title: Executive Officer

---

Date: 10/06/2025

---



## ASX, Nasdaq and Media Release

6 October 2025

### Opthea Receives A\$10.8 million R&D Tax Incentive

**Melbourne, Australia and Princeton, NJ, US, October 6, 2025** – Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a biopharmaceutical company developing novel therapies to treat diseases known to be mediated by VEGF-C and/or VEGF-D, today announced that it has received an A\$10.8 million (US\$7.2 million) research and development (R&D) tax incentive from the Australian Taxation Office. The R&D tax incentive is for research and development costs incurred in the 2024/2025 financial year, and represents the amount disclosed as a current tax receivable in the Company’s audited financial statements at 30 June 2025. The R&D tax incentive relates to both Australian and eligible overseas expenditure for the development of Opthea’s candidate, sozinibercept. The R&D Tax Incentive is an Australian Federal Government program under which companies can receive cash incentives for 43.5% of eligible research and development expenditure.

Jeremy Levin, Executive Chairman of Opthea, commented: “Australia’s R&D Tax Incentive is a vital program that encourages innovation and supports companies like Opthea as we move forward. We are taking clear and deliberate steps to advance the opportunities within our assets, with a focus on creating value for our shareholders. We will share an update on our strategic plan later this year. In the meantime, we remain committed to fiscal discipline while pursuing the best path forward for the Company.”

Authorized for release to ASX by The Board of Directors.

#### Forward-Looking Statements

This ASX announcement contains certain forward-looking statements, including within the meaning of the US Private Securities Litigation Reform Act of 1995. The words “expect”, “believe”, “should”, “could”, “may”, “will”, “plan” and other similar expressions are intended to identify forward-looking statements. Forward-looking statements in this ASX announcement include statements regarding changes in management and the Board of Directors of the Company and the timing of such changes and Opthea’s ability to continue as a going concern. Forward-looking statements, opinions and estimates provided in this ASX announcement are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current conditions. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. They involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Opthea and its directors and management and may involve significant elements of subjective judgment and assumptions as to future events that may or may not be correct. These statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to the Company’s ability to identify future product candidates, future capital requirements, the

---



development, testing, production, marketing and sale of drug treatments, regulatory risk and potential loss of regulatory approvals, clinical research organization and labor costs, intellectual property protections, continued compliance with listing requirements and other factors that are of a general nature which may affect the future operating and financial performance of the Company including risk factors set forth in Opthea's Annual Report on Form 20-F filed with the US Securities and Exchange Commission (the "SEC") on September 15, 2025, and other future filings with the SEC. Actual results, performance or achievements may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Subject to any continuing obligations under applicable law or any relevant ASX listing rules, Opthea disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this ASX announcement to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based, except as otherwise required by applicable law.

---



**Authorized for release to ASX by The Board of Directors**

**Investor Inquiries**

Email: [info@opthea.com](mailto:info@opthea.com)  
Web: [www.opthea.com](http://www.opthea.com)

***Join our email database to receive program updates:***

Tel: +61 (0) 3 9826 0399  
Email: [info@opthea.com](mailto:info@opthea.com)  
Web: [www.opthea.com](http://www.opthea.com)

**Source: Opthea Limited**

---

